To the Editor In a recent cohort biomarker study, Tie and colleagues1 demonstrated the prognostic value of circulating tumor DNA (ctDNA) analysis after either surgery or adjuvant chemotherapy in stage III colon cancer. We agree with and value the identification of longitudinal noninvasive markers of recurrence risk in patients with cancer; however, we would like to highlight additional aspects that should not be neglected in the study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zhao Z, Cai S, Wang Z. Circulating Tumor DNA as a Prognostic Marker in Stage III Colon Cancer. JAMA Oncol. 2020;6(6):932. doi:10.1001/jamaoncol.2020.0283
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: